<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2026-4795</article-id><article-id custom-type="edn" pub-id-type="custom">VSOZBY</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4795</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Контраст-индуцированная нефропатия в рентгенэндоваскулярной хирургии: современные стратегии и новые возможности</article-title><trans-title-group xml:lang="en"><trans-title>Contrast-induced nephropathy in endovascular surgery: current strategies and new potential</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3905-735X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильев</surname><given-names>Д. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasiliev</surname><given-names>D. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васильев Дмитрий Константинович — к.м.н., руководитель отдела рентгенэндоваскулярной и сердечно-сосудистой хирургии им. профессора В.П. Мазаева.</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><email xlink:type="simple">vasilyevdk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-8582-7693</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кардашова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kardashova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кардашова Маргарита Александровна — врач-кардиолог отделения РХМДЛ.</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><email xlink:type="simple">levshina.ar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9315-3801</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левшина</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Levshina</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левшина Анна Романовна — лаборант-исследователь отдела рентгенэндоваскулярной и сердечно-сосудистой хирургии им. профессора В. П. Мазаева, аспирант 1 года по направлению "Кардиология".</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p><p>ResearcherID GWU-8074-2022; Scopus Author ID 57223935450; РИНЦ Author ID 1126386</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><email xlink:type="simple">levshina.ar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор, академик РАН, директор.</p><p>Петроверигский пер., д. 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>12</day><month>09</month><year>2026</year></pub-date><volume>25</volume><issue>8</issue><fpage>4795</fpage><lpage>4795</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Васильев Д.К., Кардашова М.А., Левшина А.Р., Драпкина О.М., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Васильев Д.К., Кардашова М.А., Левшина А.Р., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Vasiliev D.K., Kardashova M.A., Levshina A.R., Drapkina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4795">https://cardiovascular.elpub.ru/jour/article/view/4795</self-uri><abstract><p>Контраст-индуцированная нефропатия остаётся одним из значимых осложнений рентгенэндоваскулярных вмешательств, увеличивая риск острого повреждения почек, прогрессирования хронической болезни почек, повторных госпитализаций и смерти. Наиболее уязвимые группы — пациенты с хронической болезнью почек, сахарным диабетом 2 типа, хронической сердечной недостаточностью, пожилые лица, а также пациенты, получающие нефротоксичные препараты. В обзоре представлены современные данные о патогенезе и факторах риска контраст-индуцированной нефропатии, методы прогнозирования (включая шкалы Mehran и Mehran 2), а также существующие профилактические стратегии: гидратация, минимизация объёма контраста, выбор типа рентгеноконтрастного вещества, отмена нефротоксичных препаратов и фармакологические вмешательства. Особое внимание уделено анализу противоречивых данных по эффективности статинов, бикарбонатов и ингибиторов натрий-глюкозного ко-транспотера 2 типа, а также ограниченной роли ингибиторов ренин-ангиотензин-альдостероновой системы и диуретиков. Рассматриваются инновационные подходы, включая карбоксиангиографию при исследовании почечных артерий и применение неорганических нитратов, эффективность которых впервые была убедительно продемонстрирована у пациентов высокого риска с острым коронарным синдромом. Объединённые данные подчёркивают необходимость дальнейших исследований, направленных на создание надёжных методов ранней диагностики, уточнение гидратационных стратегий и развитие новых ренопротективных технологий.</p></abstract><trans-abstract xml:lang="en"><p>Contrast-induced nephropathy (CIN) remains a significant complication of endovascular interventions, increasing the risk of acute kidney injury, progression of chronic kidney disease, hospital readmissions, and mortality. The most vulnerable groups include patients with chronic kidney disease, type 2 diabetes, heart failure, the elderly, and patients receiving nephrotoxic medications. This review presents current data on the pathogenesis and risk factors of CIN, prediction methods (including the Mehran and Mehran 2 scores), and existing preventive strategies (hydration, minimization of contrast volume, selection of contrast media type, discontinuation of nephrotoxic medications, and pharmacological interventions). Special attention is paid to the analysis of conflicting data regarding the efficacy of statins, bicarbonates, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, as well as the limited role of renin-angiotensin-aldosterone system inhibitors and diuretics. Innovative approaches are discussed, including carbon dioxide angiography for renal artery imaging and the use of inorganic nitrates, the efficacy of which has been convincingly demonstrated for the first time in high-risk patients with acute coronary syndrome. The combined data underscore the need for further research aimed at developing reliable early diagnostic methods, refining hydration strategies, and advancing novel renoprotective technologies.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>контраст-индуцированная нефропатия</kwd><kwd>острое повреждение почек</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>рентгеноконтрастное вещество</kwd></kwd-group><kwd-group xml:lang="en"><kwd>contrast-induced nephropathy</kwd><kwd>acute kidney injury</kwd><kwd>percutaneous coronary intervention</kwd><kwd>coronary artery disease</kwd><kwd>radiocontrast agent</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Modi K, Padala SA, Gupta M. Contrast-Induced Nephropathy. Updated January 4, 2025. Treasure Island (FL): StatPearls Publishing; 2026.</mixed-citation><mixed-citation xml:lang="en">Modi K, Padala SA, Gupta M. Contrast-Induced Nephropathy. Updated January 4, 2025. Treasure Island (FL): StatPearls Publishing; 2026.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117-314. doi:10.1016/j.kint.2023.10.018.</mixed-citation><mixed-citation xml:lang="en">Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117-314. doi:10.1016/j.kint.2023.10.018.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Moro AB, Strauch JGN, Groto AD, et al. Avaliação dos níveis de creatinina em pacientes submetidos à tomografia contrastada: uma metanálise. J Vasc Bras. 2021;20:e20200161. doi:10.1590/1677-5449.200161.</mixed-citation><mixed-citation xml:lang="en">Moro AB, Strauch JGN, Groto AD, et al. Avaliação dos níveis de creatinina em pacientes submetidos à tomografia contrastada: uma metanálise. J Vasc Bras. 2021;20:e20200161. doi:10.1590/1677-5449.200161.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016;102(8):638-48. doi:10.1136/heartjnl-2014-306962.</mixed-citation><mixed-citation xml:lang="en">Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016;102(8):638-48. doi:10.1136/heartjnl-2014-306962.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mohebi R, Karimi Galougahi K, Garcia JJ, et al. Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovasc Interv. 2022;15(7):753-66. doi:10.1016/j.jcin.2021.11.026.</mixed-citation><mixed-citation xml:lang="en">Mohebi R, Karimi Galougahi K, Garcia JJ, et al. Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovasc Interv. 2022;15(7):753-66. doi:10.1016/j.jcin.2021.11.026.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Samadian F, Dalili N, Mahmoudieh L, et al. Contrast-induced Nephropathy: Essentials and Concerns. Iran J Kidney Dis. 2018; 12(3):135-41.</mixed-citation><mixed-citation xml:lang="en">Samadian F, Dalili N, Mahmoudieh L, et al. Contrast-induced Nephropathy: Essentials and Concerns. Iran J Kidney Dis. 2018; 12(3):135-41.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Миронова О. Ю., Фомин В. В. Контраст-ассоциированное острое повреждение почек у пациентов с артериальной гипертензией и стабильной ишемической болезнью сердца. Системные гипертензии. 2020;17(3):48-52. doi:10.26442/2075082X.2020.3.200337.</mixed-citation><mixed-citation xml:lang="en">Mironova OI, Fomin VV. Contrast-associated acute kidney injury in patients with arterial hypertension and stable coronary artery disease. Systemic Hypertension. 2020;17(3):48-52. (In Russ.) doi:10.26442/2075082X.2020.3.200337.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wu MY, Lo WC, Wu YC, et al. The Incidence of Contrast-Induced Nephropathy and the Need of Dialysis in Patients Receiving Angiography: A Systematic Review and Meta-Analysis. Front Med. 2022;9:862534. doi:10.3389/fmed.2022.862534.</mixed-citation><mixed-citation xml:lang="en">Wu MY, Lo WC, Wu YC, et al. The Incidence of Contrast-Induced Nephropathy and the Need of Dialysis in Patients Receiving Angiography: A Systematic Review and Meta-Analysis. Front Med. 2022;9:862534. doi:10.3389/fmed.2022.862534.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515-9. doi:10.1016/j.amjcard.2004.03.008.</mixed-citation><mixed-citation xml:lang="en">Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515-9. doi:10.1016/j.amjcard.2004.03.008.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rudnick M, Feldman H. Contrast-Induced Nephropathy: What Are the True Clinical Consequences? Clin J Am Soc Nephrol. 2008;3(1):263-72. doi:10.2215/CJN.03690907.</mixed-citation><mixed-citation xml:lang="en">Rudnick M, Feldman H. Contrast-Induced Nephropathy: What Are the True Clinical Consequences? Clin J Am Soc Nephrol. 2008;3(1):263-72. doi:10.2215/CJN.03690907.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44(7):1393-9. doi:10.1016/j.jacc.2004.06.068.</mixed-citation><mixed-citation xml:lang="en">Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44(7):1393-9. doi:10.1016/j.jacc.2004.06.068.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021; 398(10315):1974-83. doi:10.1016/S0140-6736(21)02326-6.</mixed-citation><mixed-citation xml:lang="en">Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021; 398(10315):1974-83. doi:10.1016/S0140-6736(21)02326-6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Y, Xu X, Xue Y, et al. Mehran 2 Contrast-Associated Acute Kidney Injury Risk Score: Is it Applicable to the Asian Percutaneous Coronary Intervention Population? Clin Appl Thromb Hemost. 2022; 28:10760296221116353. doi:10.1177/10760296221116353.</mixed-citation><mixed-citation xml:lang="en">Guo Y, Xu X, Xue Y, et al. Mehran 2 Contrast-Associated Acute Kidney Injury Risk Score: Is it Applicable to the Asian Percutaneous Coronary Intervention Population? Clin Appl Thromb Hemost. 2022; 28:10760296221116353. doi:10.1177/10760296221116353.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Landi A, Chiarito M, Branca M, et al. Validation of a Contemporary Acute Kidney Injury Risk Score in Patients With Acute Coronary Syndrome. JACC: Cardiovasc Interv. 2023;16(15):1873-86. doi:10.1016/j.jcin.2023.06.015.</mixed-citation><mixed-citation xml:lang="en">Landi A, Chiarito M, Branca M, et al. Validation of a Contemporary Acute Kidney Injury Risk Score in Patients With Acute Coronary Syndrome. JACC: Cardiovasc Interv. 2023;16(15):1873-86. doi:10.1016/j.jcin.2023.06.015.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Andreucci M, Faga T, Pisani A, et al. Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. Sci World J. 2014;2014-6. doi:10.1155/2014/823169.</mixed-citation><mixed-citation xml:lang="en">Andreucci M, Faga T, Pisani A, et al. Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors. Sci World J. 2014;2014-6. doi:10.1155/2014/823169.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal Blood Purification Therapies for Prevention of Radiocontrast-Induced Nephropathy: A Systematic Review. Am J Kidney Dis. 2006;48(3):361-71. doi:10.1053/j.ajkd.2006.05.023.</mixed-citation><mixed-citation xml:lang="en">Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal Blood Purification Therapies for Prevention of Radiocontrast-Induced Nephropathy: A Systematic Review. Am J Kidney Dis. 2006;48(3):361-71. doi:10.1053/j.ajkd.2006.05.023.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Stacul F, Van Der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527-41. doi:10.1007/s00330-011-2225-0.</mixed-citation><mixed-citation xml:lang="en">Stacul F, Van Der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527-41. doi:10.1007/s00330-011-2225-0.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;1; 389(10076):1312-22. doi:10.1016/S0140-6736(17)30057-0.</mixed-citation><mixed-citation xml:lang="en">Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;1; 389(10076):1312-22. doi:10.1016/S0140-6736(17)30057-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603-14. doi:10.1056/NEJMoa1710933.</mixed-citation><mixed-citation xml:lang="en">Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603-14. doi:10.1056/NEJMoa1710933.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lombardi M, Molisana M, Genovesi E, et al. Urine alkalinisation to prevent contrast-induced acute kidney injury: the prospective, randomised, controlled, open-label TEATE trial. EuroIntervention. 2022;18(7):562-73. doi:10.4244/EIJ-D-22-00010.</mixed-citation><mixed-citation xml:lang="en">Lombardi M, Molisana M, Genovesi E, et al. Urine alkalinisation to prevent contrast-induced acute kidney injury: the prospective, randomised, controlled, open-label TEATE trial. EuroIntervention. 2022;18(7):562-73. doi:10.4244/EIJ-D-22-00010.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Филатов Д. Н. Неионные контрастные вещества (современный взгляд). Consilium Medicum. 2011;13(10):92-4. EDN: RAFOJT.</mixed-citation><mixed-citation xml:lang="en">Filatov DN. Neionnye kontrastnye veshchestva (sovremennyy vzglyad). Consilium Medicum. 2011;13(10):92-4. (In Russ.) EDN: RAFOJT.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Freitas R, Tanajura LF, Mehran R, et al. Ioxaglate Versus IoDixanol for the Prevention of Contrast-induced Nephropathy: The IDPC Trial. J Invasive Cardiol. 2023;35(6). doi:10.25270/jic/21.00249.</mixed-citation><mixed-citation xml:lang="en">Freitas R, Tanajura LF, Mehran R, et al. Ioxaglate Versus IoDixanol for the Prevention of Contrast-induced Nephropathy: The IDPC Trial. J Invasive Cardiol. 2023;35(6). doi:10.25270/jic/21.00249.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58(9):907-14. doi:10.1016/j.jacc.2011.05.023.</mixed-citation><mixed-citation xml:lang="en">Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58(9):907-14. doi:10.1016/j.jacc.2011.05.023.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Васильев Д. К., Араблинский Н. А., Шукуров Ф. Б. и др. Возможности карбоксиангиографии при лечении критического поражения почечной артерии у пациента с хронической болезнью почек. Клинический случай. Кардиоваскулярная терапия и профилактика. 2024;23(12):4189. doi:10.15829/1728-8800-2024-4189.</mixed-citation><mixed-citation xml:lang="en">Vasiliev DK, Arablinsky NA, Shukurov FB, et al. Potential of carbon dioxide angiography in the treatment of critical renal artery lesions in a patient with chronic kidney disease: a case report. Cardiovascular Therapy and Prevention. 2024;23(12):4189. (In Russ.) doi:10.15829/1728-8800-2024-4189.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SR, Ali S, Cardella J, et al. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. J Vasc Surg. 2023;78(1):201-8. doi:10.1016/j.jvs.2023.03.029.</mixed-citation><mixed-citation xml:lang="en">Lee SR, Ali S, Cardella J, et al. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. J Vasc Surg. 2023;78(1):201-8. doi:10.1016/j.jvs.2023.03.029.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Asgharpour M, Danialy R, Mirhashemi S, et al. Intravenous contrast agents in diabetic patients taking metformin; an updated review on current concepts. J Nephropathol. 2019;9(1):e05-e05. doi:10.15171/jnp.2020.05.</mixed-citation><mixed-citation xml:lang="en">Asgharpour M, Danialy R, Mirhashemi S, et al. Intravenous contrast agents in diabetic patients taking metformin; an updated review on current concepts. J Nephropathol. 2019;9(1):e05-e05. doi:10.15171/jnp.2020.05.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao H, Li Y, Xu B, et al. Metformin Can Be Safely Used in Patients Exposed to Contrast Media: A Systematic Review and Meta-Analysis. Cardiology. 2022;147(5-6):469-78. doi:10.1159/000527384.</mixed-citation><mixed-citation xml:lang="en">Qiao H, Li Y, Xu B, et al. Metformin Can Be Safely Used in Patients Exposed to Contrast Media: A Systematic Review and Meta-Analysis. Cardiology. 2022;147(5-6):469-78. doi:10.1159/000527384.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">ACT Investigators. Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation. 2011;124(11):1250-9. doi:10.1161/CIRCULATIONAHA.111.038943.</mixed-citation><mixed-citation xml:lang="en">ACT Investigators. Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation. 2011;124(11):1250-9. doi:10.1161/CIRCULATIONAHA.111.038943.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Magner K, Ilin JV, Clark EG, et al. Meta-analytic Techniques to Assess the Association Between N-acetylcysteine and Acute Kidney Injury After Contrast Administration: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220671. doi:10.1001/jamanetworkopen.2022.20671.</mixed-citation><mixed-citation xml:lang="en">Magner K, Ilin JV, Clark EG, et al. Meta-analytic Techniques to Assess the Association Between N-acetylcysteine and Acute Kidney Injury After Contrast Administration: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220671. doi:10.1001/jamanetworkopen.2022.20671.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Leoncini M, Toso A, Maioli M, et al. Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. J Am Coll Cardiol. 2014;63(1):71-9. doi: 10.1016/j.jacc.2013.04.105.</mixed-citation><mixed-citation xml:lang="en">Leoncini M, Toso A, Maioli M, et al. Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. J Am Coll Cardiol. 2014;63(1):71-9. doi: 10.1016/j.jacc.2013.04.105.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Patti G, Ricottini E, Nusca A, et al. Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Contrast-Induced Nephropathy] Trial. Am J Cardiol. 2011;108(1):1-7. doi:10.1016/j.amjcard.2011.03.00131.</mixed-citation><mixed-citation xml:lang="en">Patti G, Ricottini E, Nusca A, et al. Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Contrast-Induced Nephropathy] Trial. Am J Cardiol. 2011;108(1):1-7. doi:10.1016/j.amjcard.2011.03.00131.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe M, Aonuma K, Murohara T, et al. Prevention of Contrast-Induced Nephropathy After Cardiovascular Catheterization and Intervention With High-Dose Strong Statin Therapy in Japan — The PREVENT CINC-J Study. Circ J. 2022;86(9):1455-63. doi:10.1253/circj.CJ-21-0869.</mixed-citation><mixed-citation xml:lang="en">Watanabe M, Aonuma K, Murohara T, et al. Prevention of Contrast-Induced Nephropathy After Cardiovascular Catheterization and Intervention With High-Dose Strong Statin Therapy in Japan — The PREVENT CINC-J Study. Circ J. 2022;86(9):1455-63. doi:10.1253/circj.CJ-21-0869.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk HA, Gulumsek E, Ozturk DD, et al. The Association between SGLT2 Inhibitors Use and the Risk of Contrast Induced Acute Kidney Injury in Patients with Type 2 Diabetes. J Cukurova Anesth Surg. 2025;8(2):129-33. doi:10.36516/jocass.1654263.</mixed-citation><mixed-citation xml:lang="en">Ozturk HA, Gulumsek E, Ozturk DD, et al. The Association between SGLT2 Inhibitors Use and the Risk of Contrast Induced Acute Kidney Injury in Patients with Type 2 Diabetes. J Cukurova Anesth Surg. 2025;8(2):129-33. doi:10.36516/jocass.1654263.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Heyman SN, Aronson D, Abassi Z. SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory Concepts and Clinical Outcomes. Int J Mol Sci. 2024;25(19):10759. doi:10.3390/ijms251910759.</mixed-citation><mixed-citation xml:lang="en">Heyman SN, Aronson D, Abassi Z. SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory Concepts and Clinical Outcomes. Int J Mol Sci. 2024;25(19):10759. doi:10.3390/ijms251910759.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zang J, Liang J, Zhang X, et al. Short term sodium glucose transport protein 2 inhibitors are associated with post contrast acute kidney injury in patients with diabetes. Sci Rep. 2024;14(1):22937. doi:10.1038/s41598-024-74233-7.</mixed-citation><mixed-citation xml:lang="en">Zang J, Liang J, Zhang X, et al. Short term sodium glucose transport protein 2 inhibitors are associated with post contrast acute kidney injury in patients with diabetes. Sci Rep. 2024;14(1):22937. doi:10.1038/s41598-024-74233-7.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Luckraz H, Giri R, Wrigley B, et al. The use of the RenalGuard system in cardiac surgery with cardiopulmonary bypass: a first in man prospective, observational, feasibility pilot study. Open Heart. 2017;4(2):e000669. doi:10.1136/openhrt-2017-000669.</mixed-citation><mixed-citation xml:lang="en">Luckraz H, Giri R, Wrigley B, et al. The use of the RenalGuard system in cardiac surgery with cardiopulmonary bypass: a first in man prospective, observational, feasibility pilot study. Open Heart. 2017;4(2):e000669. doi:10.1136/openhrt-2017-000669.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wu Z, Zhang H, Jin W, et al. The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis. PLoS ONE. 2015;10(6):e0129747. doi:10.1371/journal.pone.0129747.</mixed-citation><mixed-citation xml:lang="en">Wu Z, Zhang H, Jin W, et al. The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis. PLoS ONE. 2015;10(6):e0129747. doi:10.1371/journal.pone.0129747.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Jones DA, Beirne AM, Kelham M, et al. Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J. 2024;45(18):1647-58. doi:10.1093/eurheartj/ehae100.</mixed-citation><mixed-citation xml:lang="en">Jones DA, Beirne AM, Kelham M, et al. Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J. 2024;45(18):1647-58. doi:10.1093/eurheartj/ehae100.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
